NBOMes

General Information

History

These chemicals have nearly no history of human use prior to 2010 when they first became available online. The NBOMe family of chemicals is relatively new and very little is known about this group of compounds. These chemicals may only be used with extreme caution.

25I-NBOMe Dosage

Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect). NBOMe chemicals are not active orally, and will not work if swallowed. It is recommended to avoid sublingual administration because of the reported bad taste. Buccal administration is common, placing the tab between the upper or lower gum and lip.

Sublingual

Light: 200-500 micrograms

Common: 500-1500 micrograms

Strong: 1500+ micrograms

Insufflated

Light: 100-400 micrograms

Common: 400-700 micrograms

Strong: 700+ micrograms

25C-NBOMe Dosage

Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect).

Sublingual

Light: 100-300 micrograms

Common: 300-800 micrograms

Strong: 800+ micrograms

Insufflated

Low dose: 100-300 ug (micrograms!)

Medium (typical) dose: 300-500 ug (micrograms!)

High dose: >500 ug (micrograms!)

Duration

Sublingual

Onset: 15-45 minutes

Total: 4-11 hours

Insufflated

Onset: 0-10 minutes

Total: 3-8 hours

Effects

Positive

• Strong open and closed eye visuals, including trails, color shifts, brightening, etc.
• Mood lift
• Euphoria
• Mental and physical stimulation
• Increase in associative & creative thinking
• Increased awareness & appreciation of music
• Life-changing spiritual experiences
• Erotic, sexual thoughts and sensations
• Feelings of love and empathy

Neutral

• General change in consciousness
• Pupil dilation
• Difficulty focusing
• Unusual body sensations (facial flushing, chills, goosebumps, body energy)
• Change in perception of time, time dilation
• Slight increase in heart rate
• Yawning, especially when coming up

Negative

Likelihood of negative side effects increases with higher doses.

• Confusion
• Looping
• Scrambled communication
• Nausea
• Insomnia
• Looping, recursive, out of control thinking
• Paranoia, fear, and panic
• Unwanted and overwhelming feelings
• Unwanted life-changing spiritual experiences

After effects

• Afterglow
  • An afterglow may be present until a day after use, sometimes more depending on the individual.

• Long term effects
  • A relatively high rate of HPPD has been reported (all anecdotal data!) after the use of the NBOMe chemicals.

Harm Reduction

Do not attempt to operate heavy machinery, drive, ride a bike or do anything similar. Delayed reaction time and altering of your visual perception make these kind of activities unsafe.

• Recommended time (pauses) between using the substance
  • >2 weeks for a 100% tolerance reset, but the more time the better. You have only one body, be careful with it.

• Addiction potential
  • So far no reports of addiction have surfaced.

• Risk of death
  • Most reports of death by an NBOMe chemical involve mislabeling of the drug (for example: someone insufflates 20mg of 25i-NBOMe because he/she thought it was 2C-I). This chemical is extremely potent and has a relatively low LD50 (LD50 is the dosage at which 50% of the tested population does not survive). Therefore, a mislabeling can result in death.

• Mental illness
  • Do not use when you have a history of mental illness or a family history of mental illness (such as depression, schizophrenia, psychosis, bipolar disorder, etc.).

• Heart issues
  • Do not use when you have a history of heart issues or a family history of heart issues.

Legal status

Europe

The NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011. See http://www.rg.ru/2011/10/19/narko-dok.html.

The UK Home Office announced that 25I-NBOMe would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamine. See http://www.legislation.gov.uk/ukdsi/2014/9780111110904.

America

The NBOMe series of compounds are unscheduled in the United States. It is possible that some of them would be considered analogs (of scheduled phenethylamines such as 2C-B or mescaline), in which case, sales for human consumption or possession with the intent to ingest could be prosecuted under the Federal Analogue Act. However, Virginia has recently made the 25x-NBOMe series and all its analogues schedule I; expected is that more states are to follow quickly.